Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo® 200) in the treatment of Parkinson's disease: A case series

Cases Journal

Volumn 2, Issue 7, 2009, Pages

  Sethi, Kapil D ^a   Hauser, Robert A ^b   Isaacson, Stuart H ^c   McClain, Terry ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Parkinson's Disease and Movement Disorder Center of Boca Raton   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; PERGOLIDE MESILATE; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BEDTIME DOSAGE; BRADYKINESIA; CASE REPORT; COMPULSION; DAILY LIFE ACTIVITY; DRUG DOSE INCREASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSKINESIA; FOGGY MINDED; HUMAN; MALE; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NEUROLOGIC DISEASE; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PATIENT COMPLIANCE; RESTLESSNESS; SWEATING; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT;

EID: 77953458352     PISSN: 17571626     EISSN: None     Source Type: Journal    
DOI: 10.4076/1757-1626-2-7134     Document Type: Article

References (15)

1. Olanow CW, Obeso JA, Stocchi F: Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Pract Neurol 2006, 2:382-392.
2. Holloway RG et al: Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004, 61:1044-1053.
3. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000, 342:1484-1491.
4. Grosset KA, Bone I, Grosset DG: Suboptimal medication adherence in Parkinson's disease. Mov Disord 2005, 20:1502-1507.
5. Grosset KA, Reid JL, Grosset DG: Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease. Mov Disord 2005, 20:1397-1404.
6. Birkmayer W: Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602). Wien Klin Wochenschr 1969, 81:677-679.
7. Watanabe AM, Chase TN, Cardon PV: Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes. Clin Pharmacol Ther 1970, 11:740-746.
8. Stocchi F: The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations. Expert Opin Pharmacother 2006, 7:1399-1407.
9. Jankovic J, Aguilar LG: Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat 2008, 4:743-757.
10. Hauser RA: Levodopa/carbidopa/entacapone (Stalevo). Neurology 2004, 62:S64-S71.
11. Gordin A, Kaakkola S, Teravainen H: Clinical advantages of COMT inhibition with entacapone - a review. J Neural Transm 2004, 111:1343-363.
12. Stalevo Prescribing Information [http://www.pharma.us.novartis. com/product/pi/pdf/stalevo.pdf].
13. Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A: Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord 2009, 24:541-550.
14. Delea TE, Thomas SK, Hagiwara M, Mancione L, Stacy M: Improved compliance with levodopa/carbidopa/entacapone (L/C/E; Stalevo® ) vs levodopa/carbidopa and entacapone (L/C + E) as separate tablets in Parkinson's disease (PD). Mov Disord 2007, 22:S102.
15. Sauramo A, Korpela K, Vahteristo M, Kuoppamaki M, Kailiajarvi M, Lehtinen T et al: Pharmacokinetic profile of levodopa after a single night-time dose or after repeated daily dosing of levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo® ) compared with controlled-release levodopa/carbidopa 200/50 mg (Sinemet® CR) in healthy volunteers. Ann Neurol 2008, 64:S1-S139 (Abstract T-71).